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We attempt to correlate the clinical pharmacology of dopamine replacement therapy (DRT) in 
Parkinson Disease with known features of striatal dopamine actions.  Despite its obvious 
impact, DRT does not normalize motor function, likely due to disrupted phasic dopaminergic 
signaling.  The DRT Short Duration Response is likely a permissive-paracrine effect, possibly 
resulting from dopaminergic support of corticostriate synaptic plasticity.   The DRT Long 
Duration Response may result from mimicry of tonic dopamine signaling regulation of 
movement vigor. Our understanding of dopamine actions does not explain important aspects of 
DRT clinical pharmacology.  Reducing these knowledge gaps provides opportunities to improve 
understanding of dopamine actions and symptomatic treatment of Parkinson disease. 
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Introduction: 
 Parkinson disease (PD) is a common neurodegenerative disorder and the most common 
serious movement disorder.  The defining clinical features of bradykinesia, rigidity, and resting 
tremor, accompanied by characteristic alterations of posture, gait, and voice quality, are among 
the most striking phenomena in Neurology.  Equally impressive is the marked improvement 
seen in many patients with dopamine replacement therapy (DRT).  The discovery that dopamine 
is the primary neurotransmitter of the nigrostriatal projection, whose disruption causes the 
cardinal motor features of parkinsonism, focused attention on understanding striatal dopamine 
actions.  The large literature in this field, while far from conclusive, indicates that striatal 
dopaminergic neurotransmission mediates important aspects of learning, motivation, and goal-
directed behaviors.   
The complex basic science literature on striatal dopamine suggests several important 
components of its actions.1  Disruption of striatal dopaminergic signaling should manifest in 
complex ways and it should be possible to correlate important features of the clinical response 
to DRT with basic aspects of striatal dopamine signaling.  The goal of this Grand Rounds is to 
explore these potential correlations to assist identification of mechanisms relevant to the clinical 
actions of DRT.  Similarly, failures of our present understanding of dopaminergic nigrostriatal 
signaling to explain important features of DRT clinical pharmacology point to important areas for 
future investigation.  We suggest that disruption of three key functions of striatal dopaminergic 
signaling – phasic dopaminergic signaling, permissive-paracrine dopaminergic modulation of 
corticostriate synaptic plasticity, and tonic dopaminergic signaling that estimates the background 
rate of reward - explain important features of DRT clinical pharmacology.  These potential 
correlations expose significant gaps between DRT clinical pharmacology and our present 
knowledge of dopaminergic nigrostriatal signaling. 
Dopamine Replacement Therapy Has Ceiling Effects: 
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 It is widely recognized that DRT does not restore normal function.  This is likely due to 2 
features of PD.  While most of the defining motor features of PD – tremor, bradykinesia, rigidity 
– are secondary to nigrostriatal degeneration, PD is a multifocal neurodegeneration affecting 
many brain regions, even in early disease.  Dopamine replacement resistant clinical features, 
including some gait and postural control deficits, likely reflect pathologies outside the basal 
ganglia.  But even with generally dopamine replacement responsive features, such as 
bradykinesia, it is unusual for DRT to normalize function.  The Earlier versus Later Levodopa 
Therapy in Parkinson disease (ELLDOPA) trial provides a pertinent example.2  This trial enrolled 
mildly symptomatic subjects with mean total Unified Parkinson’s Disease Rating Scale (UPDRS) 
scores of approximately 27 (mean motor component scores approximately 19).  At 9 weeks 
after study initiation, treatment with 300 or 600 mg of L-dopa per day resulted in an 
approximately 4 point change in total UPDRS scores, with most of the change attributable to 
motor score changes.  Experienced clinicians recognize that even in optimally treated patients, 
movement speed rarely normalizes and finely coordinated movements continue to be 
significantly impaired.  This is visible with simple maneuvers such as finger tapping, where 
slowing of rapid movements, progressive slowing with repetition, and movement amplitude 
decrements are demonstrated readily in the clinic. The failure of DRT to normalize motor 
function implies that some important aspect(s) of normal striatal dopaminergic signaling is 
irretrievably impaired in PD.      
DRT Has Two Major Components: 
DRT effects in PD are complex.  As noted in the seminal papers of Cotzias et al., there 
are both rapid and longer term therapeutic effects of L-dopa.3,4  While Cotzias and colleagues 
noted rapid onset of L-dopa effects, they also found that some PD subjects experienced 
continued improvement for several days after reaching stable daily L-dopa doses.  Similarly, 
some of their PD subjects experienced a slow decline in motor function over days to weeks after 
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stopping L-dopa treatment.  Muenter and Tyce subsequently characterized these 2 primary L-
dopa effects as the short duration response (SDR) and the long duration response (LDR).5,6  In 
both responses, bradykinesia, rigidity, and (usually) tremor improve with therapy.  The SDR 
begins rapidly, sometimes within minutes of L-dopa administration, lasts minutes to hours, and 
then declines, with clinical improvement roughly parallel to plasma L-dopa levels.  The LDR is 
sustained improvement that builds up over days of repeated L-dopa treatment and decays over 
similar intervals after treatment cessation.  The SDR is usually explained by correlating it with L-
dopa pharmacokinetics, which begs the question of what dopamine actions are normalized 
during the SDR.  The LDR is generally treated as an unexplained pharmacodynamic 
phenomenon.  Nutt and Holford interpreted the existence of the SDR and LDR as implying more 
than one mechanism of L-dopa action, a proposal consistent with the concept that striatal 
dopaminergic signaling has diverse actions.7   
SDR & LDR Features:   
Cotzias et al. described the LDR qualitatively in their original clinical observations of 
successful L-dopa treatment of PD.  Muenter and Tyce used a clinical disability rating scale to 
evaluate effects of L-dopa treatment.  They evaluated clinically stable, treated PD subjects after 
overnight withdrawal of L-dopa (~10 hours; the “practical off” state) and then after administration 
of their customary oral L-dopa dose.  Several subjects exhibited significant differences between 
these “off state” disability scale measurements and their pre-treatment disability scores, 
indicating improved baseline function in the “practical off” state after prolonged treatment.  
Muenter and Tyce reported also that some of their subjects exhibited functional decline 3-5 days 
after stopping L-dopa.   
LDR kinetics are incompletely understood.  Because patients often undergo repeated 
dose adjustments after initiation of therapy, and only rarely in controlled settings, it is difficult to 
measure the magnitude of the LDR after therapy initiation.  Modeling of data accumulated in the 
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DATATOP trial, which followed initially treatment naïve subjects, indicated that maximum 
benefits of L-dopa may not be achieved for months.8  LDR decline after therapy cessation is 
better studied, particularly with rigorous paradigms developed by Nutt and colleagues in which 
motor performance is measured regularly after L-dopa discontinuation.9.10.11  This is an 
operational definition of the LDR as gradually declining motor function after therapy cessation, 
and assumes that this decline is a reversal of the same phenomenon underlying gradual 
improvement after therapy initiation.  Dopaminergic therapy is withdrawn from patients with 
consistent responses to stable treatment regimens in controlled settings.  Some standard motor 
task, such as finger tapping rates, is used to assess motor performance.  Motor performance off 
medication can be compared with baseline (treated) performance and also with subjects’ pre-
treatment performances (Figure 1). SDR effects can be estimated by measuring the effects of 
acutely administered L-dopa, including intravenous L-dopa administration to sidestep the 
pharmacokinetic complexities of oral L-dopa administration.   
These studies suggest that the LDR declines over days to weeks.  Pharmacodynamic 
modeling of declining motor performance after treatment cessation estimates the half-life of L-
dopa and bromocriptine motor effects, predominantly the LDR, at approximately 8 days.12  This 
inference is consistent with results of the ELLDOPA trial, in which the L-dopa treated 
participants had better UPDRS scores than placebo treated participants after a 2 week washout 
period.2  The ELLDOPA experience highlights an important aspect of the LDR; it complicates 
interpretation of disease-modifying trial outcomes.  
 By various measures, the LDR accounts for 30% to 50% of the total (SDR + 
LDR) response to L-dopa and is responsible for much of the sustained-uniform response to L-
dopa in patients with early PD.6.13  The LDR is present in more advanced PD but diminishes with 
disease progression, with the SDR becoming a more important treatment component.9.11,14,15,16  
In a longitudinal study following PD subjects over a 4 year interval, Nutt et al. used their rigorous 
LDR evaluation protocol and documented more rapidly declining LDRs with disease 
Page 6 of 49
John Wiley & Sons
Annals of Neurology
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
 
7 
 
progression.11  The SDR persisted and increased in magnitude with advancing disease, 
perhaps because more rapidly declining LDRs resulted in lower baseline levels of motor 
function at the times of acute L-dopa administrations.  The declining LDR and increase of the 
SDR accounts partly for the emergence of motor fluctuations.  The SDR but not the LDR is 
associated with dyskinesias.  
Analogous results were found in Kempster’s careful longitudinal study of a small group 
(N=34) of PD subjects followed for over 2 decades from treatment inception (Figure 1B).17-20  
The SDR was preserved in some subjects with PD of many years duration.  Those advanced 
PD subjects with declining SDRs tended to exhibit overt dementia, suggesting that pathologies 
outside the basal ganglia are responsible for the loss of the SDR (Figure 2).  Alternatively, 
patients may have developed dose-limiting side-effects as non-motor features became more 
prominent. 
A crucial point is that LDR induction is seen only with repetitive treatments, as it is not 
reinstated after a single intravenous dose of L-dopa during drug holidays.21  Relatively 
infrequent treatment may be sufficient to induce the LDR since daily, relatively high (250 mg) L-
dopa doses are reported to elicit the LDR in early PD.22   
  
Pharmacokinetic vs Pharmacodynamic LDR Mechanisms:   
Two broad categories of LDR mechanisms were considered: pharmacokinetic and 
pharmacodynamic.6.13  The pharmacokinetic hypothesis postulated the existence of a brain 
reservoir that accumulates L-dopa and slowly releases dopamine.  A plausible hypothesis was 
that surviving nigrostriatal terminals were a central reservoir of dopamine synthesized from 
exogenous L-dopa and the decline of the LDR with disease progression could be explained by 
gradual loss of residual nigrostriatal terminals.  A critical prediction is that the LDR should be 
specific for L-dopa and not occur with dopamine agonists.  This prediction was falsified by 
several studies.12,23,24,25  The LDR is sustained by intravenous infusion of the dopamine agonist 
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apomorphine and is induced by treatment with D2-receptor selective dopamine agonists.12,23,24,25  
The decay rate of agonist induced LDR was essentially identical to the decay rate of the L-dopa 
induced LDR.12,24.25  The LDR is also documented in Dopa Responsive Dystonia (DRD).26  The 
LDR in DRD has similar decay kinetics to those found in PD, but DRD has essentially normal 
presynaptic dopamine storage capacity.  If the LDR is based on presynaptic storage of 
dopamine, the LDR of DRD should exceed that of PD.26  The decline of the LDR with disease 
progression does not clearly parallel the decline in putaminal nigrostriatal terminal density.  In 
Kempster’s cohort, off-state disability, which is a partially a function of LDR magnitude, declined 
linearly over 2 decades.17-20  In contrast, a prospective, longitudinal study of putaminal 
nigrostriatal dopaminergic terminal loss in PD with [11C]dihydrotetrabenazine positron emission 
tomography indicates exponential decline in terminal density, approaching a plateau in more 
advanced disease.27  Kordower et al. studied nigrostriatal terminal integrity as a function of 
disease duration in a set of well-characterized post-mortem PD specimens and described a 
similar non-linear trajectory of putaminal nigrostriatal terminal loss.28  In more advanced PD 
subjects, Kordower et al. document an almost complete absence of nigrostriatal terminals in the 
dorsal striatum.  These results point away from a pharmacokinetic explanation and implicate a 
pharmacodynamic effect of dopamine signaling.   
Mapping Clinical Pharmacology onto Known Dopamine Functions: 
DRT clinical pharmacology has 3 major features to correlate with normal striatal 
dopaminergic actions – the ceiling effects of treatment, the SDR, and the LDR.  A correlate of 
the ceiling effect would have to be an aspect of striatal dopamine action that is irretrievably 
disrupted with nigrostriatal terminal degeneration in PD. The temporal and other features of the 
SDR and LDR offer criteria for plausible mapping of these phenomena onto known striatal 
dopaminergic functions.  Mechanisms responsible for the SDR should act with time courses in 
the minutes to hours range.  The persistence of the SDR in advanced PD indicates that the 
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SDR does not require many nigrostriatal terminals.  In contrast, changes in mechanisms 
responsible for the LDR should occur over days to weeks and require multiple and/or chronic 
exposures to dopaminergic stimulation.  The LDR is elicited by dopamine agonists with 
relatively long half-lives, suggesting that it is a function of tonic dopamine action.   
Organization of the Nigrostriatal Projection: 
 Substantia nigra (SN) dopaminergic neurons constitute a tiny fraction of human brain 
neurons with an estimated total of ~1.2 million (~600,000 per side) neurons.29  Each neuron of 
this small population gives rise to large axonal arborizations with particularly dense innervation 
of dorsal striatal projection neurons. Projections from the most medial portion of the SN 
complex, the ventral tegmental area, target other forebrain targets such as ventral striatum, 
frontal cortex, and amygdala.  Within the striatum, a single SN neuron may contact as many as 
75,000 striatal neurons.30  This “broadcast” connectional anatomy suggests that striatal 
dopaminergic neurotransmission conveys general signals.   
SN dopaminergic neurons project topographically to striatal subregions with reciprocal 
striatonigral afferents from their projection target regions. This architecture is not entirely closed 
as there is some overlap in nigrostriatal neuron projections.31  Different striatal regions exhibit 
functional specialization as they are nodes in roughly parallel and functionally differentiated 
circuits that course through the whole cortico-basal ganglia-thalamic-cortical loop.32  In crude 
terms, more anterior regions such as the caudate are specialized for cognitive functions, the 
more ventral regions are specialized for limbic (motivational) functions, and the dorsal putamen 
for motor functions.  It is likely that there is complex subregional functional specialization of 
cortico-basal ganglia-thalamic-cortical loops.  The regional specialization of striatal regions and 
corresponding functional specialization of cortico-basal ganglia-thalamic-cortical loops suggests 
that striatal dopaminergic signaling performs uniform operations across the striatum with 
functional specificity residing at the level of striatal circuitry.  
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The “broadcast” concept is consistent also with the ultrastructure of nigrostriatal 
terminals.  Striatal projection neuron dendrites exhibit prominent spines which are the 
termination sites of both cortical (and thalamic) and SN dopaminergic projections.  The 
canonical microcircuit of a striatal projection neuron spine consists of a glutamatergic excitatory 
cortical (or thalamic) neuron terminal synapsing on the spine “head” and a dopaminergic 
terminal synapsing on the spine “neck” (Figure 3).  This triadic arrangement is consistent with 
dopamine action regulating striatal projection neuron function via modulation of corticostriate 
synapse function.   
Phasic Striatal Dopamine Signaling:   
 Dopaminergic nigrostriatal neurons exhibit tonic regular firing punctuated by phasic 
bursts of action potentials that trigger bolus release of dopamine within the striatum.  These 
bursts result in brief (100-300 milliseconds) and sharply contoured pulses of striatal dopamine 
release with substantial, transient increases in extracellular dopamine.  Most of the physiologic 
literature on striatal dopaminergic signaling is devoted to explaining the role(s) of phasic activity.  
Convergent theoretical and experimental results over the past couple of decades suggests that 
phasic nigrostriatal dopaminergic signaling mediates reinforcement learning (for concise 
reviews, see Glimcher33 or Kerflin and Janak34; for detailed review, see Schultz35).  An important 
concept is that phasic nigrostriatal dopaminergic neurotransmission mediates reward prediction 
error (RPE) signals for reinforcement learning.  In the best-validated models of reinforcement 
learning, temporal difference models, the value of an organism’s current state is estimated as 
the net value of future expected rewards. High value rewards with a high probability of 
attainment in the near future contribute greatly to the current state value. Conversely, potential 
future rewards with lower intrinsic value, a lower probability of attainment, and/or longer latency 
to attainment contribute less. At each time point, the organism compares their current state 
value estimate to their previous prediction; the difference is the RPE.  These RPEs are then 
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used to update ensembles of cached sets of estimated values of environmental stimuli and 
actions.  The concept that nigrostriatal dopaminergic signaling mediates reinforcement learning 
dovetails nicely with the concept that nigrostriatal dopaminergic function is important for habit 
learning.36  
In seminal experiments by Schultz and colleagues, phasic nigrostriatal dopaminergic 
neuron activity exhibits RPE signal properties.  Schultz’s group studied substantia nigra (SN) 
dopaminergic neuron activity as monkeys learned associations between visual cues and 
rewards.  In untrained animals, reward presentation was followed rapidly by a burst of SN 
neuron activity.   Phasic dopaminergic neuron activity and the inferred striatal dopamine bolus 
elicited by this unexpected reward constitute a positive RPE signal.  As animals learned the 
stimulus reward associations, the burst of SN activity following the reward subsides, while the 
visual cue is followed by a burst of SN activity (and presumed striatal dopamine bolus).  
Migration of the positive RPE signal from a previously unexpected reward to the predicting cue 
is an explicit prediction of temporal difference models (Figure 4).  Also consistent with temporal 
difference models, omission of an expected reward results in reduced nigrostriatal neuron 
activity.  Temporal difference models result in other predictions that can be evaluated 
experimentally.  One example is predictions about the magnitude of positive reward prediction 
error signals and the history of rewards.  In clever experiments, Bayer and Glimcher 
demonstrated that firing rates of dopaminergic SN neurons under conditions of varying rewards 
follow the predicted relationships.37   
While a large body of work supports the embodiment of RPE signals in phasic 
nigrostriatal dopaminergic neuron activity, recent results suggest somewhat different roles in 
other aspects of behavior. Dopaminergic neurotransmission and reinforcement learning can be 
dissociated under specific conditions.38,39.40  Palmiter and colleagues, for example, used mice 
with ablated aromatic acid decarboxylase genes to demonstrate learning in typical 
reinforcement learning paradigms in the absence of dopaminergic signaling.39   
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Recent technical advances make it possible to measure calcium transients in striatal 
dopaminergic terminals and axons in awake, behaving mice.  These transients likely reflect 
phasic nigrostriatal neuron bursting.  Parker et al. recorded rapid calcium transients in 
dorsomedial (analogous to caudate) and ventral (limbic) striata of mice performing a reversal 
learning task.41  Consistent with the concept of phasic dopaminergic signaling embodying RPEs, 
dorsomedial and ventral striatal rapid calcium transients were associated with rewards and 
reward predicting cues.  Dorsomedial striatal calcium transients, however, were also associated 
with movement direction selection.  This result is consistent with involvement of dopaminergic 
signaling in movement execution independent of learning or motivation, but is also consistent 
with more complex reinforcement learning models.  These results indicate also that functional 
specificity of dopaminergic signaling resides at the level of striatal subregions.  
In a technical tour de force, Howe and Dombeck recorded these calcium transients in 
dorsal striatal dopaminergic terminals and axons in awake, locomoting mice.42  Rapid calcium 
transients were associated with locomotion accelerations and not with unpredicted rewards.  
Optogenetic stimulation mimicking dorsal striatal phasic dopamine release produced 
accelerations.  In strong control experiments, Howe and Dombeck demonstrated reward 
associated calcium transients in ventral striatal nigrostriatal axons-terminals.  This work 
associates dorsal striatal phasic dopamine signaling with specific kinematic features of 
movement, consistent with other reports of movement-related phasic changes in nigrostriatal 
dopamine neuron firing.43,44,45   
Phasic dorsal nigrostriatal dopaminergic signaling likely plays a critical role in important 
aspects of fine motor performance distinct from its well established role in reinforcement 
learning based on primary rewards.  Some conceptual models of nigrostriatal phasic signaling in 
motor performance suggest that dopaminergic signaling is involved in feedback control of motor 
performance by matching sensory feedback about motor performance to internal 
representations of desired actions.46,47,48   These concepts bear a general family resemblance to 
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temporal difference models of reinforcement learning in that they incorporate updating internal 
representations of action outcomes.  In an ingenious experiment, Gadagkar et al. evaluated the 
role of phasic nigrostriatal signaling in fine coordination of a complex motor act, zebra finch 
singing.49  By manipulating auditory feedback, Gadagkar et al. were able to correlate 
dopaminergic neuron behavior with perceived song performance.  Phasic activation and 
suppression of dopaminergic neurons correlated well with perceived better than expected and 
worse than expected song performance, respectively.  These results are consistent with phasic 
nigrostriatal signaling participating in evaluation of motor performance relative to some internal 
benchmark. 
The Ceiling Effect of Treatment and Loss of Phasic Signaling: 
 Given the impressive degree of posterior putaminal striatal nigrostriatal terminal loss in 
early PD, likely in excess of 60% of terminals, it is hard to imagine that normal phasic 
dopaminergic signaling is preserved in motor specialized striatal regions in PD patients.50  The 
likely disruption of normal phasic signaling probably has both anatomic and functional 
components.  Many posterior putamen neurons undoubtedly lose much of their dopaminergic 
innervation.  While the remaining nigrostriatal neurons probably continue to exhibit phasic firing, 
it is very likely that magnitude of phasic dopamine release diminishes.51,52 The dopamine that is 
released is also likely to be cleared more slowly because extracellular dopamine is normally 
removed rapidly by dopamine transporters on nigrostriatal terminals.  Loss of nigrostriatal 
terminals, with consequent loss of dopamine transporters, results in extended residence of 
dopamine in the extracellular space.51 Loss of many dopaminergic terminals and reduced 
capacity to rapidly clear extracellular dopamine markedly degrade the pulsatile character of 
normal phasic nigrostriatal signaling.  This is not likely to be corrected by L-dopa 
supplementation and will not be mimicked by dopamine agonists.   
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It is likely that loss of normal phasic signaling accounts for persistent motor deficits in 
well-treated, early PD patients, suggesting an interesting conclusion.  Given the impressive 
functional improvements in early PD patients, phasic dopamine signaling represents only a 
fraction of relevant dopamine actions.  In terms of movement control, phasic striatal dopamine 
signaling may be a “fine-tuning” mechanism superimposed on other dopamine actions that likely 
account for the SDR and LDR.   
Dopaminergic Maintenance of Corticostriate Synaptic Plasticity – A Mechanism for the SDR?: 
 Key features of the SDR - its close relationship to plasma L-dopa levels, relatively rapid 
onset and offset, and persistence in the presence of substantial nigrostriatal terminal loss - 
indicate a direct effect of L-dopa derived dopamine on striatal neurons via a hormone-like effect. 
This is also consistent with the SDR-like effects of dopamine agonists, as initially documented 
by Cotzias in experiments with apomorphine.53  As dopamine acts via modulatory G-protein 
coupled receptors, this cannot be a conventional fast inhibitory or excitatory neurotransmitter 
effect. The canonical triadic arrangement of striatal projection neuron spines, corticostriate 
neuron terminals, and closely adjacent nigrostriatal terminals suggests a particularly important 
role for dopaminergic signaling in modulating corticostriate neurotransmission.  A strong 
candidate SDR mechanism is dopaminergic maintenance of corticostriate synaptic plasticity. 
 Yttri and Dudman recently evaluated the role of corticostriate synaptic plasticity in a 
methodologically sophisticated study of movement control.54 They demonstrated that brief 
closed loop optogenetic photostimulation of striatal projection neurons during limb movements, 
mimicking physiologic striatal projection neuron bursting, produced increasing changes in limb 
movement velocity. Selectively stimulating direct or indirect pathway neurons during fast 
movements increased or decreased velocity, respectively. Importantly, the opposite occurred 
with photostimulation only during slow movements. That is, direct pathway activation now 
slowed movements, while indirect pathway activation sped them up. Furthermore, increased 
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and decreased limb movement velocities were present during non-stimulated trials, suggesting 
persistent changes in corticostriatal networks, inferred to be secondary to changes in 
corticostriate synapse plasticity. The effects of optogenetic stimulation manifested over minutes, 
and with cessation of optogenetic stimulation, limb movement velocities returned gradually to 
their pre-stimulation states. In a complementary analysis, Yttri & Dudman developed a 
computational model of corticostriate synaptic plasticity governing striatal projection neuron 
bursting and movement kinematics that nicely reproduced the results of their experiments.  This 
sophisticated analysis and set of experiments links modulation of corticostriate synapse 
plasticity to specific kinematic features of movement.   
  The optogenetic stimulation approach utilized by Yttri & Dudman did not directly alter 
striatal dopaminergic neurotransmission.  The inferred changes in corticostriate synapse 
plasticity took place in the absence of changes in nigrostriatal dopaminergic signaling and likely 
against the background of tonic ambient dopamine levels.  Yttri & Dudman showed also that 
behavioral effects of optogenetic stimulation were blocked by systemically administered 
dopamine antagonists.  A large literature demonstrates that normal modulation of corticostriate 
synaptic plasticity requires dopamine receptor activation (see reviews by Calabresi and 
colleagues).55,56  This is true for both long term potentiation (LTP) and long term depression 
(LTD), including the spike timing dependent plasticity (STDP) thought to be critical for fine 
modulation of synaptic strength.57,58,59.60,61,62  The great majority of experiments studying 
dopaminergic modulation of corticostriate synaptic plasticity utilize ex vivo slice preparations in 
which phasic dopaminergic signaling is absent.  This strongly suggests that tonic dopamine 
receptor activation has a permissive effect on normal corticostriate synaptic plasticity 
independent of phasic dopamine release.  This conclusion is supported by computational 
modeling of dopamine effects on STDP.63   
 A permissive-paracrine effect of dopamine on corticostriate synaptic plasticity is 
consistent with SDR features.  The time course of minutes to hours for the effects documented 
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by Yttri and Dudman, as well as in ex vivo slice preparations, is consistent with the SDR.  The 
requirement for some degree of striatal dopamine receptor activation, though not necessarily 
precise modulation of extracellular striatal dopamine levels, is also consistent with the 
incomplete response to DRT.  This is not to argue that phasic changes in striatal dopamine 
levels have no consequence - the magnitude and timing of striatal dopamine receptor activation 
likely modulate corticostriate synaptic plasticity. We suggest that this fine modulation is subtle, 
however, at least in terms of motor control.   The concept of a permissive-paracrine tonic 
dopamine effect on corticostriate synaptic plasticity as the basis for the SDR is consistent with in 
vivo data in treated PD patients.  Positron emission tomography studies of extracellular striatal 
dopamine levels indicate that PD patients with motor fluctuations and dyskinesias exhibit larger, 
briefer changes in extracellular dopamine levels with L-dopa treatment than patients with stable 
responses.64  These effects likely reflect progressive loss of nigrostriatal terminals, and 
consequently a reduced “buffer” compartment to maintain striatal extracellular dopamine levels 
within a broadly physiologic limit.65  With disease progression, striatal extracellular dopamine 
levels increasingly depend on the unregulated synthesis and release of dopamine from non-
dopaminergic neurons after L-dopa treatment. Serotoninergic neurons are believed to be 
especially important in this respect.66 
 The waning SDR in advanced PD may reflect loss or dysfunction of corticostriate 
synapses.  Braak and Del Tredici note the frequent presence of α-synuclein inclusions in 
cortical layer V, the site of corticostriate projection neuron perikarya, in advanced PD.  They 
suggest that this cortical pathology leads to corticostriate synaptic dysfunction and loss, with 
consequent loss of the DRT response.67 This hypothesis is consistent with Kempster’s 
description of waning SDR in overtly demented patients.19  
The LDR and Learning: 
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 The gradual onset and decline of the LDR is consistent with some form of neuronal 
learning as its basis. Therefore, in contrast to our proposal that corticostriate synapse plasticity 
mediates the SDR, it has also been suggested that corticostriate synapse plasticity underlies 
the LDR.68 Interesting experiments with rodent models of parkinsonism explored this concept.   
 Beeler and colleagues studied acquisition and extinction of motor performance in 
homozygous Pitx3 knockout mice.69 In these mutants, nigrostriatal neurons degenerate 
gradually with marked (~90%) loss of dorsal striatal dopamine.  These mice exhibit grossly 
normal motor function but are impaired on some learning tasks, including a rotarod task.  In a 
possible LDR analogue, L-dopa administered once daily prior to testing sessions restored the 
ability of Pitx3 knockout mice to improve performance with trial repetition.  L-dopa administration 
outside trial sessions had no effect.  With L-dopa treatment discontinuation, performance did not 
deteriorate immediately but decayed over several days with repeated task performance.  
Critically, rotarod performance of rats trained on a different task (treadmill running) in the 
absence of levodopa did not decay. This indicates that the “learning” effects of levodopa loss 
were task-specific. Measurement of striatal dopamine levels confirmed that pharmacokinetic 
factors could not account for the slow decline in motor performance after L-dopa 
discontinuation.  These results are consistent with the concept that some form of dopamine 
mediated learning underlies the LDR.   
 One potential problem with invoking this form of motor learning as the basis for the LDR 
is that the LDR manifests as a general improvement in motor performance, as opposed to 
specific deficits in learning new tasks. This fact may be reconciled with a learning conception of 
the LDR by dopamine replacement preventing unlearning (extinction) of previously learned 
motor behaviors.  In a complementary experiment, Dowd and Dunnett used the rat unilateral 6-
hydroxydopamine lesion model to study an analogue of declining motor function after DRT 
discontinuation.70,71  Rats were trained in a lateralized reaction time task and rewarded for 
selecting a target either to the right or left of midline after presentation of an instructive cue.  
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Unilateral 6-hydroxydopamine lesions were performed after training to a high level of accuracy.  
After a period of weeks without training, rats were retested.  Task performance was initially 
almost normal, but performance contralateral to the lesioned side declined over several days.  
As with the Pitx3 mice experiments, the initially normal performance excludes a motor deficit per 
se.  The decline in motor performance contralateral to the 6-hydroxydopamine lesion closely 
paralleled the decline in performance of unlesioned rats after unidirectional reward omission, 
and similar results were observed using intrastriatal injections of dopamine antagonists.72 
Striatal dopaminergic denervation mimicked extinction of a learned motor act.   
 A learning conception of the LDR can be reconciled with diffuse effects of DRT in 
maintaining the ability to perform previously learned motor behaviors. However, it does not 
obviously account for the general effect of DRT in improving bradykinesia.  An interesting 
literature on striatal dopaminergic modulation of speed or strength of movement may cast light 
on the nature of the LDR.  
Vigor and Striatal Dopamine Signaling:   
Another important concept of nigrostriatal dopamine action is that it plays an important 
role in regulating “vigor;” the speed or strength of actions.  Salamone and others argued 
persuasively that a great deal of experimental data are best understood in the context of a role 
for striatal dopamine in efficiently allocating effort by scaling actions to motivational states.73,74,75 
Interfering, for example, with striatal dopamine signaling reduces the effort an animal is willing to 
put into obtaining a food reward.   All movements incur costs, if only some energy costs, and 
more vigorous (faster or more sustained) actions incur higher costs. In the view of Salamone et 
al., striatal dopaminergic signaling is crucial for estimating the context dependent cost/benefit 
tradeoffs of actions.  This idea fits well with a number of observations about PD.  An obvious 
potential clinical correlate is bradykinesia.  There is considerable literature on deficient 
movement amplitude scaling in PD, and decrementing amplitude of simple movements and 
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phenomena like micrographia are common clinical observations in PD. More speculatively, 
deficient vigor could form part of the substrate of the apathy found commonly in PD patients. 
 Mazzoni et al tested the hypothesis that bradykinesia results from abnormal effort 
allocation in PD using a speed-accuracy trade-off task.76 Subjects were asked to move their 
hand, within a specific velocity range, into a target area. The task was repeated until 20 
movements were executed with an appropriate velocity. PD patients and control subjects 
exhibited similar accuracy on velocity-matched movements, but it took more trials for PD 
patients to generate movements in the target velocity range. This was interpreted as PD 
patients having a different perception of the cost/benefit ratio of movements compared to control 
subjects.76  Baraduc et al. obtained analogous results in DBS treated PD subjects performing a 
reaching task, and other recent studies of reward/effort trade-offs in PD subjects are consistent 
with dopaminergic modulation of vigor.77,78,79,80  Electrophysiologic studies of MPTP-treated non-
human primates are also consistent with dopaminergic modulation of vigor.81   
 Panigraphi et al. examined the role of nigrostriatal dopaminergic signaling in “vigor” 
using a mouse model of progressive nigrostriatal degeneration.82 MitoPark mice have a 
selective deletion of a crucial mitochondrial transcription factor restricted to midbrain 
dopaminergic neurons.  These mice exhibit gradual post-natal death of midbrain dopaminergic 
neurons and slowly progressive bradykinesia over months.  Panigraphi et al. trained MitoPark 
mice to perform a joystick task with varying thresholds of limb movement velocities needed to 
obtain rewards.  Young MitoPark mice readily learned the task and performed well.  Task 
performance declined, primarily due to impaired velocity of limb movements, in parallel with 
nigrostriatal neuron degeneration.  During testing sessions, the limb movement velocity 
thresholds for reward were varied in blocs. Bradykinetic MitoPark mice appropriately modulated 
limb velocity with bloc changes, even though limb velocities were often inadequate to obtain 
rewards.  These analyses indicated that MitoPark mice learned the appropriate reward 
contingencies but were not able to scale limb movement velocity appropriately.  These results 
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parallel the human experiments of Mazzoni et al.76 and Baraduc et al.77, and suggest that striatal 
dopamine deficiency causes a defect in the regulation of movement vigor, not a learning deficit 
per se.   
 A complementary experiment by Cagniard et al. also supports a role for tonic dopamine 
signaling in modulating vigor.83  These workers used mice with an inducible knockdown of the 
dopamine transporter (IDATKD) that results in a chronic, moderately hyperdopaminergic state.  
After DAT knockdown, these mice exhibit increased tonic dopaminergic midbrain neuron activity 
with normal phasic activity.  Cagniard et al. trained IDATKD mice in a standard task in which 
increasing effort is required to obtain rewards.  To eliminate the possibility that DAT knockdown 
would affect task learning, animals were trained to a high performance level prior to induced 
DAT knockdown.  After DAT knockdown, these animals are willing to work harder than wild-type 
mice for equivalent rewards.  In an appropriate control experiment, Cagniard et al. showed that 
IDATKD mice had normal learning on a control task after induced KD knockdown. 
Reconciling Learning and Vigor:   
In an effort to reconcile these two apparently disparate concepts of dopaminergic 
signaling, Niv et al. elaborated a temporal difference model of reinforcement learning in which 
subjects make choices about both action selection and action vigor.84 In any given setting, 
differing choices of actions and degree of vigor will incur differing benefits and costs.  The goal 
is to optimize the net value of rewards per unit of time, which is the value of the chosen action 
minus the value of costs incurred by the action (Figure 5).  The costs include the vigor with 
which the action is performed.  An important element of this calculation is to estimate the cost 
not only of one alternative action versus another but also the cost of doing nothing.  In economic 
terms, the real cost of a decision – the opportunity cost – is the relative value of the 
alternative(s) not chosen. An important point made by Niv et al. is that less vigorous actions not 
only delay the immediate rewards associated with the chosen actions but also delay all future 
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rewards. How, then, to estimate the opportunity cost of inaction?  In the Niv et al. model, the 
opportunity cost of inaction is the preceding average rate of rewards.  If the average rate of 
rewards is high, then doing nothing is costly and more vigorous performance is incented. If the 
average rate of rewards is low, the penalty of inaction is lower and there is less incentive to act 
vigorously.  Niv et al. show that outputs from their model simulations duplicate results of typical 
animal experiments examining response vigor. 
Accounting of rewards and reward magnitudes over long intervals would be necessary to 
accurately estimate the prior average rate of rewards.  Niv et al. suggest that this signal is tonic 
striatal dopamine signaling. In their simulations, manipulating the average rate of reward has an 
identical effect to manipulating striatal dopamine in typical experiments. Niv et al. demonstrate 
that increasing the average rate of reward has a generally “energizing” effect on actions, with 
action vigor increasing not only for the specific actions in a learned task but also for actions 
generally.  This is a potential correlate of DRT relief of bradykinesia.  
Niv et al. point out another implication of their model.84 In a particularly interesting set of 
simulations, Niv et al. report that the slower responding resulting from simulating reduced tonic 
dopamine signaling - reduced prior average rate of reward - results in less switching between 
different actions.  Less vigorous actions are energetically less costly, which raises the 
opportunity cost of switching to a different action.  This simulated outcome may be analogue of 
phenomena such as freezing of gait when attempting turns and pallilalia.  
The Niv et al. model is consistent with some recent experimental results.85,86  Hamid et 
al. examined striatal extracellular dopamine across multiple time scales in rats performing  a 
complex adaptive decision making task.  Minute to minute changes in dopamine concentration 
correlated with task reward rate and a measure of task vigor.85  Beeler et al. employed 
dopamine transporter knockdown mice (DATKD) with moderate, chronic elevations in striatal 
dopamine and a clever behavioral paradigm that required mice to both learn new responses for 
rewards and to adjust the amount of effort needed to maintain their body weight.86  DATKD mice 
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learned as well as control mice but worked harder to obtain equivalent rewards. DATKD mice 
acted with greater vigor, exhibiting distorted coupling between the magnitudes of reward and 
effort, presumably because their chronically elevated striatal dopamine levels leads to 
misperception of the prior average rate of rewards. 
Vigor and the LDR: 
Invigorating movement via increased striatal tonic dopaminergic signaling as a mimic of 
increasing the background rate of rewards is a good hypothesis to explain the LDR.  While 
based largely on correlation with preclinical experimental and theoretical literature, this 
hypothesis is consistent with the work of Mazzoni et al. and others who have examined vigor in 
PD subjects (see above).76,77,78,79,80   In an interesting experimental correlate, Panigraphi et al. 
treated bradykinetic MitoPark mice with daily L-dopa, which improved both locomotion and limb 
movement velocities.82  In a result strongly reminiscent of the LDR, bradykinesia improved 
gradually over several weeks (Figure 6).  This non-physiologic but clinically relevant DRT 
improved estimation of appropriate movement vigor. This result is consistent with a gradual 
effect of dopamine replacement in correcting dysregulated matching of motivational state to 
action.  The equation of tonic dopaminergic modulation of vigor and the LDR, however, raises 
some interesting questions and opens the door to potentially interesting experiments.   
 If the dopaminergic signal provided by L-dopa and dopamine agonists is the basis for 
computing the average rate of reward, how is that signal analyzed and translated into 
invigorated action?  The LDR phenomenon clearly builds up (and declines) over days to weeks. 
This implies some kind of relatively long duration plasticity.  To date, neither human nor 
preclinical experiments have explored this aspect of the LDR.  In the Hamid et al. experiments, 
which demonstrated correlations between movement vigor, striatal extracellular dopamine 
concentrations, and average rate of rewards, the duration of measurements was over hours, not 
days.  The experiment of Mazzoni et al. examined treated PD treated subjects.  Other human 
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experiments examining the relationship between movement vigor and energy costs in PD 
studied chronically treated subjects in the “practical off” state and after acute treatment.78,79,80   
 To test the concept that the LDR results from chronic treatment restoring a more normal 
relationship between movement vigor and perceived costs of movement, experiments could be 
performed in treatment naïve PD subjects, in the same subjects immediately after treatment 
initiation, and weeks after achievement of stable treatment regimens.  The LDR = Increased 
Vigor induced by DRT hypothesis predicts that untreated patients should have markedly 
abnormal reward/effort trade-offs in behavioral paradigms of the type used by Mazzoni et al., 
that these abnormalities would not improve immediately after treatment initiation, and that the 
vigor-perceived cost relationship would improve gradually over days to weeks.  Improvements in 
the vigor-perceived cost relationship should correlate with measures of overall clinical 
improvement, particularly bradykinesia.  Falsification of these predictions would suggest 
strongly that normalizing vigor modulation is not the basis of the LDR.   
The MitoPark mice utilized by Panigraphi et al. might be a useful platform to explore 
mechanisms underlying this type of relatively long duration plasticity.  This model appears to 
exhibit an analogue of the LDR (see above) and temporal correlations between the gradual 
improvement in motor performance following L-dopa treatment and potential mechanisms would 
provide logical points of departure in the search for specific mechanisms underlying the LDR. 
Potential Neuronal Mechanisms of the LDR: 
 While mimicry of tonic striatal dopaminergic modulation of vigor is an attractive 
hypothesis to explain the LDR, this is a psychophysical construct that does not speak to the 
neuronal mechanisms by which it is implemented. If corticostriate plasticity underlies the SDR, 
where do circuit changes occur that mediate the LDR?  If tonic dopamine signaling represents 
the average rate of reward, there must be an “accounting” or “integrating” mechanism that 
stores the information conveyed by tonic dopamine and adjusts responses accordingly.  Recent 
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rodent and non-human primate lesion experiments indicate that the striatum mediates longer 
term estimates of prior reward histories, influencing both action selection and action vigor.87,88  
 Zhuang et al. put forward the interesting hypothesis that the LDR results from chronic 
DRT normalization of corticostriate synaptic plasticity.68  As discussed above, a permissive-
paracrine effect of DA in maintaining corticostriate synaptic plasticity is a more plausible 
mechanism for the SDR.  The computational model of corticostriate synaptic plasticity of Yttri & 
Dudman, however, has an interesting feature that could be the basis for a corticostriate synaptic 
plasticity based explanation of the LDR.54  In the Yttri & Dudman model, the range of movement 
velocities and underlying corticostriate synaptic plasticity changes are assumed to exist in the 
form of Gaussian distributions of potential states.  Rewarded movements shift the means of the 
distributions.  To model maintenance of a physiological range of movement velocities, this 
model incorporates a “restorative set point” that tends to pull movement velocities back towards 
the original mean.  Extending this model to explain both the SDR and the LDR, a permissive-
paracrine effect of DA maintains relatively normal corticostriate synaptic plasticity, accounting 
for the SDR.  The magnitude of tonic DA action (average background rate of reward) influences 
the “set point,” determining the mean of the distribution of permissible movement velocities.  
This hypothesis provides a mechanistic basis for our psychophysical explanation of the LDR 
and may be testable in rodent parkinsonism models.   
Another possibility is that the LDR is based on plasticity that is an emergent property of 
basal ganglia circuits under tonic striatal dopaminergic stimulation.  This concept derives from 
the clinical observation that subthalamic or pallidal deep brain stimulation (DBS) in PD patients 
does not reach peak effects (at least for bradykinesia) for days to weeks after stimulation 
parameter changes.  In an analogous experiment, Wang et al. observed persistent beneficial 
effects, lasting days after cessation of stimulation, of a novel subthalamic DBS protocol in 
MPTP-treated non-human primates.89  The physiologic basis of these effects is unknown but the 
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fact they are elicited by STN DBS suggests extra-striatal mechanisms unrelated directly to 
striatal dopamine actions. 
 Another possible class of explanations for the LDR is some form of structural plasticity 
within the basal ganglia.  Experimental nigrostriatal neuron degeneration or administration of 
dopamine receptor antagonists are described by several groups as producing structural 
changes in in striatal projection neuron dendrites, striatal interneuron connectivity, and 
corticostriate synapses.90,91,92,93,94,95,96  Of note, dendritic spine loss after 6-OHDA lesioning is 
confined to indirect pathway SPNs, and D2 receptor agonists are capable of inducing the LDR.92 
Administration of L-dopa to mice with 6-hydroxydopamine striatal lesions produces dendritic 
alterations in striatal projection neurons.95  These kinds of plastic changes are not restricted to 
the striatum.  Fan et al. demonstrated a relatively rapid, within weeks, increase in the density of 
external globus pallidus – subthalamic neuron synapses following 6-hydroxydopamine striatal 
lesions in mice.90   
As pointed out some years ago by Nutt and Holford, understanding mechanisms 
underlying the LDR might allow development of interventions to prolong the period in which the 
LDR plays a major role in response to dopaminergic agents.7 This is usually the period of 
maximum function, and even modest extensions of that period could have a major impact on 
patient quality of life.  
Striatal Dopamine Actions Through the Lens of DRT Clinical Pharmacology: 
 Correlation of DRT clinical pharmacology with some features of striatal dopamine 
actions suggests a tripartite model of striatal dopamine modulation of motor performance 
(Figure 7a).  Relatively rapid, over seconds to minutes, “fine tuning” of motor acts is secondary 
to phasic dopamine signaling.  Slower, over the course of minutes to hours, permissive-
paracrine effects of dopaminergic support of corticostriate synaptic plasticity accounts for the 
SDR.   Finally, tonic striatal dopamine signaling provides a measure of the prior rate of reward 
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and the motivational “set point” for action vigor, which broadly influences motor performance. 
This set point provides the foundation for the modulatory activities of corticostriate synapse 
plasticity.  Each one of these putative components is incompletely understood, and what may be 
the most quantitatively important, the LDR, is likely the least understood.   
An important conceptual limitation of this model is that it is based on phenomena 
occurring in a multisystem neurodegenerative disorder.  Analogies between clinical phenomena 
and normal actions may be confounded by compensatory mechanisms in the disease state.  
Pathologies outside the basal ganglia may also be salient (as discussed briefly in the context of 
the SDR).  Nonetheless, this model appears to identify important areas for future investigation 
and suggests some testable predictions.     
This model also suggests an alternative way of looking at PD progression (Figure 7b).  
Important milestones for PD patients include the emergence of motor fluctuations and DRT non-
responsive symptoms like cognitive and postural-gait deficits.97   
The intervals between these milestones can be characterized in terms of changes in the 
3 different striatal dopamine signaling actions.  The early “honeymoon” period of treated PD is 
characterized by loss of phasic striatal dopamine signaling, but DRT partially restores 
corticostriate synaptic plasticity and partially normalizes reward/effort scaling (i.e, vigor).  A 
second phase is characterized by decline of the mechanism(s) underpinning estimation of 
appropriate levels of vigor. In the final phase, extra-basal ganglia pathologies lead to non-DRT 
responsive features and decline of the SDR because of cortical pathologies impairing 
corticostriate plasticity.  
Potential Clinical Implications: 
 Our analysis may have some implications for contemporary clinical practice, clinical 
experiments, and novel therapeutic interventions.  If the LDR is a function of tonic, stable, 
striatal dopamine signaling, then interventions to restore or maintain tonic signaling might be 
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beneficial.  A potentially relevant existing clinical intervention is continuous L-dopa delivery via 
carbidopa-levodopa intestinal gel (CLIG).  A recent PET imaging experiment indicates that CLIG 
produces sustained, increased striatal dopamine levels.98  It would be potentially interesting to 
determine if CLIG improves or reinstates the LDR in more advanced PD subjects.   
As dopamine agonists can induce and sustain the LDR, this could be a rationale for 
relatively early use of dopamine agonists.  This would be a somewhat different rationale than 
prior, and largely unsupported, suggestions that early agonist treatment retards disease 
progression or delays the emergence of dyskinesias.99  Agonist treatment, however, comes with 
increased risk of side-effects, notably impulse control disorders, compared to L-dopa 
preparations.  A plausible explanation for the lower therapeutic index of dopamine agonists is a 
variant of the “over-dose” hypothesis.100  Dopamine agonists indiscriminately activate dopamine 
receptors in all parts of the striatal complex, including the ventral striatum.  With relative 
preservation of nigrostriatal innervation in the ventral striatum, treatment with dopamine 
agonists likely causes pathological activation of ventral striatal dopamine receptors, distorting 
the motivational functions of this part of the striatal complex.    
 An intervention that improved tonic dopamine signaling in the dorsal striatum selectively 
might sustain the LDR without the risk of dopamine agonist associated impulse control 
disorders.  Novel gene therapy methods may allow sub-regionally targeted and modulated 
increases in tonic dopamine signaling in the PD striatum.101,102  Clinical trials are underway with 
some of these approaches and it might be possible to assess LDR effects of these 
interventions.   
 As discussed above (Potential Neuronal Mechanisms of the LDR), it is also plausible 
that the LDR results from basal ganglia circuit changes and that STN DBS might induce LDR-
like effects.  If correct, this would be an additional rationale for earlier use of STN DBS.  STN 
DBS induction of enhanced LDR or LDR-like effects might partly explain the reported benefits of 
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relatively early use of STN DBS.103  Evaluation of potential LDR effects should be feasible in this 
patient population and might cast light on LDR mechanisms.  
 Further study of the LDR in the context of existing and novel clinical interventions has 
the potential to both improve understanding of this important phenomenon and improve clinical 
practice.  
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Figure Legends: 
 
Figure 1.  Clinical characteristics of the SDR and LDR effects. (A) Schematic representation of 
the SDR and LDR effects (adapted from Nutt et al., Short and long-duration responses to 
levodopa during the first year of therapy, Ann Neurology, 1997, Figure 1).9 Drug-naïve PD 
patients were given IV levodopa infusions, and motor function assessed with a finger-tapping 
task. After 4 days, a second infusion was given. Patients returned after one year and underwent 
the same protocol after PD medications were held overnight.  The LDR is visible as the upward 
migration of motor performance immediately prior to the first IV levodopa infusion after one year 
of treatment.  The SDR immediately follows IV levodopa infusions. (B) From Clissold et al., 
Longitudinal study of the motor response to levodopa in Parkinson’s disease, Mov Disord, 2006, 
Figure 5.20 Schematic of the progression of the magnitude of the short- (open boxes; SDR) and 
long- (solid boxes; LDR) duration responses to levodopa. The solid line represents disability in 
the untreated state and is a partial function of the magnitude of the LDR. With disease 
progression, the LDR wanes and the SDR becomes a relatively larger component of the 
levodopa response. Higher scores indicate increasing disability. 
 
Figure 2.  The natural history of LDR and SDR with disease progression in Kempster’s cohort. 
From Alty et al., Longitudinal study of the levodopa motor response in Parkinson’s disease: 
relationship between cognitive decline and motor function, Mov Disord, 2009, Figure 5.19 
Modified Webster Scores of PD patients in the practical “off” state (tops of boxes) and 60-90 
minutes after their usual levodopa dose (bottom of boxes) as a function of disease duration for 
non-demented (black boxes) and demented (MMSE < 24, white boxes) patients. The Modified 
Webster Score is a standardized assessment of motor function, with higher scores indicating 
worse function. Note the diminished magnitude of the SDR in demented vs non-demented 
patients. 
 
Figure 3. Schematic diagram of the striatal “synaptic triad.” Cortical (and thalamic afferents) 
synapse on striatal projection neuron spine heads with dopaminergic terminals on spine necks.  
Dopaminergic synapses are well positioned to both modulate glutamatergic signaling onto 
medium spiny projection neurons and plasticity of corticostriate synapses. 
 
Figure 4.  Temporal difference model reward prediction error signaling. The red trace indicates 
actual state value; the blue trace indicates estimated state value; the black trace represents 
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dopamine neuron firing rates (FR). In a hypothetical task, a cue predicts a reward and reward 
timing with 100% certainty. Note that the state value gradually increases after the predictive cue 
as the rewarding event moves closer. On trial 1 (top panel), the agent is unaware of the cue-
reward association, so the state value estimate is low until the reward is delivered. This is 
reflected as a phasic increase in DA neuron firing at reward delivery. After many trials (“mid-
session”), the agent associates the cue with reward according to the rules of temporal difference 
models, but is not yet certain of the 100% correspondence between cue and reward. Therefore, 
the state value estimate jumps twice, reflected in two smaller phasic DA firing increases. With 
more experience, the agent understands that the cue predicts reward with 100% certainty, and 
the phasic DA signal migrates entirely to the cue.   
 
Figure 5. Schematic representation of varying opportunity cost of inaction (tonic dopamine 
signaling) on vigor.  Optimal latency to initiate movement (as a surrogate for response vigor). 
Top – high tonic dopamine, bottom – low tonic dopamine. Black curves – cost of movement 
vigor, which is very high at short latencies and independent of tonic dopamine levels. Red lines 
– opportunity cost of the action relative to inaction, which has a higher slope at higher tonic 
dopamine levels. Blue curves – net action value as a function of latency (expected action value 
minus the cost of vigor and opportunity cost). The maximum net action value (optimum latency) 
is indicated with an asterisk. Note the optimal latency to maximize future rewards shifts to the 
right with decreasing tonic dopamine levels. 
 
Figure 6. LDR-like effect of levodopa in MitoPark mice.  Number of locomotor bout initiations 
(“progressions”, panel A) and maximal locomotor velocity (panel B) in MitoPark (MP) and 
wildtype (WT) mice moving freely in an open field. MitoPark mice initiated fewer locomotor bouts 
with lower peak velocities as their midbrain dopamine neurons degenerated (red lines). Once 
treated with levodopa, both measures of motor function returned to near baseline levels, but 
only with repeated dosing (dashed blue lines). Modified for formatting from Panigrahi et al, 
Dopamine is Required for the Neural Representation and Control of Movement Vigor, Cell, 
2015, Figure 6).80 
 
Figure 7. (A) Proposed dopamine action “pyramid” as related to the clinical pharmacology of 
DRT.  Phasic dopamine (DA) release acts on a very short time-scale and is responsible for 
“fine-tuning.” It is lost in early PD, explaining why dopamine replacement therapy cannot fully 
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restore motor function. Dopamine supports normal corticostriatal synaptic plasticity, which 
operates on intermediate time scales (minutes to hours) and is responsible for the SDR. Tonic 
dopamine signaling indicates the average rate of reward over hours to weeks, and is 
responsible for the LDR. (B) Proposed changes in dopamine actions during progression of 
Parkinson Disease. In the “honeymoon period,” the LDR allows infrequent dosing of dopamine 
replacement therapy to provide stable motor function. As the LDR wanes, motor fluctuations 
and dyskinesias emerge, but the preserved SDR allows at least temporary restoration of motor 
function with DRT. With continued disease progression, pathology spreads to cortex and cortical 
afferents become dysfunctional or degenerate, reducing the SDR. In many patients, SDR 
decline is paralleled by other extrastriatal pathologies that contribute to disability.   
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Figure 1.  Clinical characteristics of the SDR and LDR effects. (A) Schematic representation of the SDR and 
LDR effects (adapted from Nutt et al., Short and long-duration responses to levodopa during the first year of 
therapy, Ann Neurology, 1997, Figure 1).9 Drug-naïve PD patients were given IV levodopa infusions, and 
motor function assessed with a finger-tapping task. After 4 days, a second infusion was given. Patients 
returned after one year and underwent the same protocol after PD medications were held overnight.  The 
LDR is visible as the upward migration of motor performance immediately prior to the first IV levodopa 
infusion after one year of treatment.  The SDR immediately follows IV levodopa infusions. (B) From Clissold 
et al., Longitudinal study of the motor response to levodopa in Parkinson’s disease, Mov Disord, 2006, 
Figure 5.20 Schematic of the progression of the magnitude of the short- (open boxes; SDR) and long- (solid 
boxes; LDR) duration responses to levodopa. The solid line represents disability in the untreated state and is 
a partial function of the magnitude of the LDR. With disease progression, the LDR wanes and the SDR 
becomes a relatively larger component of the levodopa response. Higher scores indicate increasing 
disability.  
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Figure 2.  The natural history of LDR and SDR with disease progression in Kempster’s cohort. From Alty et 
al., Longitudinal study of the levodopa motor response in Parkinson’s disease: relationship between 
cognitive decline and motor function, Mov Disord, 2009, Figure 5.19 Modified Webster Scores of PD patients 
in the practical “off” state (tops of boxes) and 60-90 minutes after their usual levodopa dose (bottom of 
boxes) as a function of disease duration for non-demented (black boxes) and demented (MMSE < 24, white 
boxes) patients. The Modified Webster Score is a standardized assessment of motor function, with higher 
scores indicating worse function. Note the diminished magnitude of the SDR in demented vs non-demented 
patients.  
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Figure 3. Schematic diagram of the striatal “synaptic triad.” Cortical (and thalamic afferents) synapse on 
striatal projection neuron spine heads with dopaminergic terminals on spine necks.  Dopaminergic synapses 
are well positioned to both modulate glutamatergic signaling onto medium spiny projection neurons and 
plasticity of corticostriate synapses.  
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Figure 4.  Temporal difference model reward prediction error signaling. The red trace indicates actual state 
value; the blue trace indicates estimated state value; the black trace represents dopamine neuron firing 
rates (FR). In a hypothetical task, a cue predicts a reward and reward timing with 100% certainty. Note that 
the state value gradually increases after the predictive cue as the rewarding event moves closer. On trial 1 
(top panel), the agent is unaware of the cue-reward association, so the state value estimate is low until the 
reward is delivered. This is reflected as a phasic increase in DA neuron firing at reward delivery. After many 
trials (“mid-session”), the agent associates the cue with reward according to the rules of temporal difference 
models, but is not yet certain of the 100% correspondence between cue and reward. Therefore, the state 
value estimate jumps twice, reflected in two smaller phasic DA firing increases. With more experience, the 
agent understands that the cue predicts reward with 100% certainty, and the phasic DA signal migrates 
entirely to the cue.    
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Figure 5. Schematic representation of varying opportunity cost of inaction (tonic dopamine signaling) on 
vigor.  Optimal latency to initiate movement (as a surrogate for response vigor). Top – high tonic dopamine, 
bottom – low tonic dopamine. Black curves – cost of movement vigor, which is very high at short latencies 
and independent of tonic dopamine levels. Red lines – opportunity cost of the action relative to inaction, 
which has a higher slope at higher tonic dopamine levels. Blue curves – net action value as a function of 
latency (expected action value minus the cost of vigor and opportunity cost). The maximum net action value 
(optimum latency) is indicated with an asterisk. Note the optimal latency to maximize future rewards shifts 
to the right with decreasing tonic dopamine levels.  
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Figure 6. LDR-like effect of levodopa in MitoPark mice.  Number of locomotor bout initiations 
(“progressions”, panel A) and maximal locomotor velocity (panel B) in MitoPark (MP) and wildtype (WT) 
mice moving freely in an open field. MitoPark mice initiated fewer locomotor bouts with lower peak velocities 
as their midbrain dopamine neurons degenerated (red lines). Once treated with levodopa, both measures of 
motor function returned to near baseline levels, but only with repeated dosing (dashed blue lines). Modified 
for formatting from Panigrahi et al, Dopamine is Required for the Neural Representation and Control of 
Movement Vigor, Cell, 2015, Figure 6).80  
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Figure 7. (A) Proposed dopamine action “pyramid” as related to the clinical pharmacology of DRT.  Phasic 
dopamine (DA) release acts on a very short time-scale and is responsible for “fine-tuning.” It is lost in early 
PD, explaining why dopamine replacement therapy cannot fully restore motor function. Dopamine supports 
normal corticostriatal synaptic plasticity, which operates on intermediate time scales (minutes to hours) and 
is responsible for the SDR. Tonic dopamine signaling indicates the average rate of reward over hours to 
weeks, and is responsible for the LDR. (B) Proposed changes in dopamine actions during progression of 
Parkinson Disease. In the “honeymoon period,” the LDR allows infrequent dosing of dopamine replacement 
therapy to provide stable motor function. As the LDR wanes, motor fluctuations and dyskinesias emerge, but 
the preserved SDR allows at least temporary restoration of motor function with DRT. With continued disease 
progression, pathology spreads to cortex and cortical afferents become dysfunctional or degenerate, 
reducing the SDR. In many patients, SDR decline is paralleled by other extrastriatal pathologies that 
contribute to disability.    
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